GlassScriptPhysician profile
Daryl C Emery
NPI 1396720421
$1,662.86
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $221 · 2021: $385 · 2022: $499.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $938.94 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $137.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $134.00 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.65 | 2019-2022 | |
| Irhythm Technologies, INC. | $74.04 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $52.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $51.56 | 2019 | |
| Edwards Lifesciences Corporation | $49.27 | 2019 | |
| Amgen INC. | $43.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.04 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.66 | 2019 | |
| Pfizer INC. | $11.19 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Emery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.